BN 52021, BN-52021, ginkgolide B, ginkgolide B, (1beta)-isomer, Ginkolide B
Name | Ginkgolide B | ||
PubChem CID | 6324617 | ||
Molecular Weight | 424.4g/mol | ||
Synonyms |
BN 52021, BN-52021, ginkgolide B, ginkgolide B, (1beta)-isomer, Ginkolide B |
||
Formula | C₂₀H₂₄O₁₀ | ||
SMILES | CC1C(=O)OC2C1(C34C(=O)OC5C3(C2O)C6(C(C5)C(C)(C)C)C(C(=O)OC6O4)O)O | ||
InChI | 1S/C20H24O10/c1-6-12(23)28-11-9(21)18-8-5-7(16(2,3)4)17(18)10(22)13(24)29-15(17)30-20(18,14(25)27-8)19(6,11)26/h6-11,15,21-22,26H,5H2,1-4H3/t6-,7+,8-,9+,10+,11+,15+,17+,18+,19-,20-/m1/s1 | ||
InChIKey | SQOJOAFXDQDRGF-MMQTXUMRSA-N | ||
CAS Number | 15291-77-7 | ||
ChEMBL ID | CHEMBL514432 | ||
Drug Bank ID | DB06744 | ||
Structure |
Download
2D
MOL
3D
MOL
|
Chineses Pinyin | YinXingYe | ||
Use Part | Leaf | ||
Habitat | China | ||
Flavor | Sweet, Bitter, Astringent | ||
Meridian Tropism | Heart, Lung | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Ginkgoales
-->Family: Ginkgoaceae
-->Genus: Ginkgo
-->Species: Ginkgo biloba
|
Chineses Pinyin | YinXing | ||
Habitat | ShenYang, GuangZhou, JiangSu, ZheJiang, AnHui, FuJian, JiangXi, ShanDong, ShangHai, GuiZhou, YunNan | ||
Flavor | Sweet; Bitter; Astringent | ||
Meridian Tropism | Heart; Lung | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Ginkgoales
-->Family: Ginkgoaceae
-->Genus: Ginkgo
-->Species: Ginkgo biloba
|
Pair Name | Ginkgolide B, Cisplatin | |||
Partner Name | Cisplatin | |||
Disease Info | [ICD-11: 2B66.Z] | Oral cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
Down-regulation | Expression | PTAFR | hsa5724 | |
In Vitro Model | Ca9-22 | Gingival squamous cell carcinoma | Homo sapiens (Human) | CVCL_1102 |
HO-1-N-1 | Buccal mucosa squamous cell carcinoma | Homo sapiens (Human) | CVCL_1284 | |
Result | These results suggest that PAFR is a therapeutic target for modulating CDDP sensitivity in OSCC cells. Thus, GB may be a novel drug that could enhance combination chemotherapy with CDDP for OSCC patients. |